SK1 I
Alternative Names: BML 258; SK1-ILatest Information Update: 28 Mar 2024
At a glance
- Originator Enzo Biochem; Virginia Commonwealth University
- Developer Enzo Biochem
- Class Anti-inflammatories; Antineoplastics; Hepatoprotectants; Small molecules
- Mechanism of Action Sphingosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune hepatitis; Haematological malignancies; Liver cancer; Solid tumours; Systemic lupus erythematosus; Ulcerative colitis
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA
- 28 Mar 2024 No recent reports of development identified for preclinical development in Ulcerative-colitis in USA
- 28 Jun 2023 No recent reports of development identified for preclinical development in Liver-cancer in USA